Tandem Diabetes Care (Nasdaq:TNDM) shares fell after hours today on second-quarter results that topped the consensus sales forecast.
Shares of TNDM fell 14% to $12.40 apiece in post-market trading after the release of the earnings on Wednesday, Aug. 6. Today, they are down 26.3% to $10.60 apiece.
The San Diego-based automated insulin delivery technology developer reported losses of $52.4 million. That equals 78¢ per share on sales of $240.7 million for the three months ended June 30, 2025.
Tandem — one of the largest diabetes tech companies in the world — recorded a 70% bottom-line slide deeper into the red on a sales increase of 8.5%.
Losses per share landed 38¢ behind expectations on Wall Street. Sales topped the forecast as experts expected $238.4 million in revenue.
Read more about Tandem and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.
Highlights included an early access program for its t:slim X2 insulin pump paired with Abbott’s FreeStyle Libre 3 CGM in the U.S. The company also won CE mark for its Mobi pump with Control-IQ+ technology and filed with the FDA for extended wear use of its SteadiSet infusion set. Finally, the company completed a feasibility study to advance the development of a fully closed-loop automated insulin delivery system.
“In the second quarter, we increased U.S. pump shipments while strengthening our business model and improving operational efficiency,” said John Sheridan, president and CEO. “Looking at the remainder of the year, we are advancing our product development and commercial initiatives, which positions us well for sustained double-digit growth and enhanced profitability.”
Tandem narrowed its guidance for 2025, as it now expects $1 billion in sales.
“We expect to reach $1 billion in worldwide 2025 sales, which is a significant milestone for our company,” said Leigh Vosseller, EVP and CFO. “Our narrowed guidance reflects insights gained in the first half of the year, including our U.S. growth expectations as we progress our commercial transformation, increased benefit from accelerated pharmacy channel initiatives and greater contributions from international sales.”
